Jpmorgan Chase & CO Infla Rx N.V. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$1.25 - $2.75 $40,818 - $89,801	-32,655 Reduced 98.06%	645 $1,000
Q3 2023 Nov 14, 2023	SELL	$2.66 - $4.33 $48,725 - $79,316	-18,318 Reduced 35.49%	33,300 $99,000
Q2 2023 Aug 11, 2023	SELL	$2.05 - $6.1 $41,215 - $122,640	-20,105 Reduced 28.03%	51,618 $230,000
Q1 2023 May 11, 2023	BUY	$1.66 - $3.1 $102,858 - $192,085	61,963 Added 634.87%	71,723 $139,000
Q4 2022 Feb 13, 2023	BUY	$2.11 - $3.25 $20,338 - $31,326	9,639 Added 7966.12%	9,760 $30,000

Q3 2022 Nov 14, 2022	BUY	$1.32 - $3.14 $159 - $379	121 New	121 $0
Q2 2022 Aug 11, 2022	SELL	$0.78 - $1.9 $419 - $1,022	-538 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.83 - $4.48 $830 - $2,033	-454 Reduced 45.77%	538 $1,000
Q4 2021 Feb 10, 2022	BUY	$2.35 - $5.58 $900 - $2,137	383 Added 62.89%	992 $5,000
Q3 2021 Nov 12, 2021	BUY	$2.25 - $3.03 $1,370 - $1,845	609 New	609 $2,000

13.8M

12.9K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $76.5M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.